Momotaro-gene (MTG) develops gene therapy products to treat solid cancer based on MTG’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, secreted  REIC/Dkk-3 proteins by cancer cells and normal cell components in tumor tissue promotes anti-tumor immunity by activating dendritic cells and natural killer (NK) cells. Based on these novel dual mechanisms, MTG is expanding its pipelines with successful clinical studies. BiGEN participated in Series A fundraising in 2017.

JUNTEN BIO is a biotech company that develops cell therapy products using its unique technology of inducing immunotolerance in patients who undergo liver or kidney transplantation. JUNTEN BIO’s regenerative medicine is autologous T cells cultured with donor T cells and antibodies. The autologous T cells can obtain the ability to induce immunotolerance to donor derived organs, which allows reduction or discontinuation of immunosuppressant after organ transplant. BiGEN participated in Series A fundraising in 2018.

Noile-Immune Biotech (NIB) focuses on the development and commercialization of next generation CAR-T cells targeting solid cancers. NIB develops the PRIME (PRoliferation-Inducing and Migration-Enhancing) CAR-T technology secreting IL-7 and CCL19. The PRIME technology improves proliferation and trafficking into solid cancers of not only CAR-T cells but also patient’s endogenous immune cells. BiGEN participated in Series A fundraising in 2018, Series B fundraising in 2020, and Series C fundraising in 2021.